Relmada Therapeutics RLMD
NASDAQ RLMD
$4.47 +0.20 (+4.57%)
As of: Nov 11, 2026 · 2:14 PM EST

Relmada Therapeutics (RLMD) Return on Capital Employed [ROCE] (2014 - 2026)

Updated

Relmada Therapeutics (RLMD) recorded Return on Capital Employed [ROCE] of -29.63% in Q2 2026, up 336.47 percentage points from -366.11% a year earlier and up 10.12 percentage points from the prior quarter.

Analysis

Relmada Therapeutics (RLMD) Return on Capital Employed [ROCE] (2014 - 2026) Analysis & Trends

For FY2025, Relmada Therapeutics reported Return on Capital Employed [ROCE] of -93.10%, up 43.54 percentage points from FY2024.

  • Annual Return on Capital Employed [ROCE] has a five-year change of -35.19 percentage points (FY2020 to FY2025).
  • Across earlier years, Return on Capital Employed [ROCE] came in at -136.64% in FY2024 (-44.90 pp), -91.74% in FY2023 (+0.06 pp), -91.80% in FY2022 (-11.07 pp) and -80.74% in FY2021 (-22.83 pp).
  • The Q2 2026 figure is the highest quarterly Return on Capital Employed [ROCE] since Q2 2020.
  • On a year-over-year basis, Return on Capital Employed [ROCE] has increased for three consecutive quarters, with an average year-over-year change of -20.41 percentage points over the last eight quarters.
  • Peak year-over-year performance for Return on Capital Employed [ROCE] in the last five years was a gain of 336.47 percentage points in Q2 2026, against a drop of 285.91 percentage points in Q3 2025 at the low end.
  • Per Business Quant, the preceding three quarters came in at -39.75% (Q1 2026), -123.10% (Q4 2025) and -451.66% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Relmada Therapeutics 455.48 Mn -103.11 Mn - -29.63%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -29.63%
Mar 31, 2026 -39.75%
Dec 31, 2025 -123.10%
Sep 30, 2025 -451.66%
Jun 30, 2025 -366.11%
Mar 31, 2025 -251.04%
Dec 31, 2024 -207.24%
Sep 30, 2024 -165.75%
Jun 30, 2024 -133.95%
Mar 31, 2024 -125.34%
Dec 31, 2023 -113.76%
Sep 30, 2023 -107.84%
Jun 30, 2023 -111.45%
Mar 31, 2023 -112.65%
Dec 31, 2022 -102.35%
Sep 30, 2022 -86.75%
Jun 30, 2022 -79.58%
Mar 31, 2022 -67.70%
Dec 31, 2021 -88.48%
Sep 30, 2021 -136.12%
API Access

Relmada Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=RLMD&period=max&api_key=YOUR_API_KEY